



EPROPA: Project's official media launch

Index:

<i>Project's official media launch</i>	1
<i>Together we make progress</i>	1
<i>A European network dedicated to connecting Patients</i>	2/3
<i>More infos</i>	4

WALCE

HQ based at Thoracic Oncology Unit (San Luigi Hospital)

Regione Gonzole, 10

10043 Orbassano (TO)
(Italy)

Tel. +39 011 9026980

info@womenagainstlungcancer.eu

www.womenagainstlungcancer.eu



On **December 16, 2020**, **EPROPA** (European Program for **RO**utine testing of **P**atients with **A**dvanced lung cancer) was officially presented to media, clinicians and patients and to 9 pharmaceutical companies (*Merck, MSD, Pfizer, Roche, AstraZeneca, BeiGene, Lilly, Amgen, Blueprint, Incytes*) that support this program.

Following you can find a selection of the most valuable articles released at the launch event of EPROPA:

<https://www.lastampa.it/torino/2020/12/16/news/>

https://www.corriere.it/salute/sportello_cancro/

On **December 28, 2020**, the laboratory received and analyzed the first sample, officially starting the operational part of the project. .

What is EPROPA?

EPROPA (European Program for **RO**utine testing of **P**atients with **A**dvanced lung cancer) is a support program designed and promoted by **WALCE** (**W**omen **A**gainst **L**ung **C**ancer in **E**urope) to offer to patients with lung tumors specific tests and possibly personalized treatments.



A digital article on the website of the Italian press, Corriere della Sera

Together we make progress

EPROPA (European Program for **RO**utine testing of **P**atients with **A**dvanced lung cancer) is a program addressed to European patients with oncogene-addicted advanced Non Small Cell Lung Cancer (NSCLC) to increase the opportunities of molecular diagnostics and

facilitate the access to clinical trials.

Which is the main goal??

The main goal of EPROPA is to generate a free-of-charge molecular screening platform for tumor characterization in order to increase the detection of oncogenic drivers (frequent

or rare) in NSCLC patients.

At the same time, EPROPA will optimize patients access to biomarker-driven clinical trials.



A European network dedicated to connecting patients:



To increase their molecular screening

The advent of Next-Generation Sequencing in the management of NSCLC patients had improved their therapeutic opportunities.



To facilitate their accrual in clinical trials

Defining the molecular landscape of these patients allows to identify alterations actionable by targeted therapies.



To provide them a logistic support

To match this information with the accessibility into clinical trials is of paramount relevance toward better patients' outcome and WALCE provides free logistical support during the pathway.

A structured network of institutions and companies

The aim of EPROPA is to create a European Research Network, involving Centers of Expertise in the treatment of lung cancer, different Pharma Companies and other entities, named the University of Turin and the International Association for the Study of Lung Cancer (IASLC) that have endorsed this program.



PROMOTED BY



ENDORSED BY



SUPPORTED BY UNRESTRICTED GRANTS OF




epropra.eu

Thank you all of you and your teams for your dedication and continued efforts.

Here we are introducing EPROPA newsletters, which we hope will give you a regular update on the project progress:

Number of patients registered: 6

Number of centres registered: 6



Molecular TESTS in progress: 6

Molecular TESTS performed: 2

We examined SNVs, CNVs, gene fusions, and indels from 161 unique genes to help inform drug discovery research and clinical trial research programs. We performed library construction of DNA and RNA from formalin-fixed paraffin embedded (FFPE) tumour samples. We support patients' enrolment within biomarker-driven clinical trials available in Europe.

HQ based at Thoracic Oncology Unit (San Luigi Hospital)
Regione Gonzole, 10
10043 Orbassano (TO) | Italy
Tel. +39 011 9026980
info@womenagainstlungcancer.eu
Facebook | Twitter

www.womenagainstlungcancer.eu

Fighting Lung Cancer Together.



About WALCE

WALCE (Women Against Lung Cancer in Europe) is a non-profit Organisation based in Italy and networking at European level, founded in 2006 with the primary aim to increase women's awareness about the significant incidence and mortality of lung cancer in female population and to support patients affected by this disease (and their families).

WALCE currently provides accurate and updated information about lung cancer in terms of prevention, diagnosis and treatment, and it wants to promote communication strategies aim to aware public opinion and decision makers on damages of smoking.

WALCE is mainly involved in: information and education dedicated to patients and their families, patient support programs and primary prevention.



More infos

How can you get any information?

Check the website: <https://www.epropa.eu/en/>

Here you can find information about:

- *participating procedures;*
- *tumour sample shipment instructions;*
- *molecular analysis and clinical trials.*

How can you enter in EPROPA platform?

- 1) Access to <https://www.epropa.eu/en>
- 2) Download the form and e-mail to: stefania.vallone@womenagainstlungcancer.eu
- 3) You will receive an email to finalize the process registering to the website platform: www.epropa.eu/portal

Biological Material: the samples for analysis must be preferably FFPE blocks of tumor tissue available (which will be returned at the end of the analysis) or 20 blank sections of the same (not returned), a paper copy of the report must be added. We provide to evaluate the material: in case of its inadequacy, the analysis will not be carried out; in case of its insufficiency, a further sending will be requested.